Mitsubishi Tanabe Pharma Corporation CEO Net Worth

Last Updated Mar 10, 2025
CEO NameYasushi Fukuoka
NationalityJapan
Net Worth Estimation$5 million

Yasushi Fukuoka, current CEO of Mitsubishi Tanabe Pharma Corporation, has an estimated net worth of around $5 million, primarily derived from executive compensation, bonuses, and shareholdings in the company. Detailed financial disclosures, stock performance, and compensation reports from Mitsubishi Tanabe Pharma contribute to this estimation.

Yasushi Fukuoka's estimated net worth of $5,000,000 is 5% of the highest CEO net worth in healthcare ($90,000,000) and 50% of the minimum ($10,000,000). His net worth is significantly below the category's average CEO net worth.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Yasushi Fukuoka Performance in Mitsubishi Tanabe Pharma Corporation

Yasushi Fukuoka, CEO of Mitsubishi Tanabe Pharma Corporation, demonstrates strategic leadership by prioritizing innovation and global expansion in pharmaceutical development. His decision-making emphasizes R&D investment and collaboration, driving advancements in treatment solutions and pipeline growth. Under Fukuoka's leadership, the company has strengthened its market position and improved overall performance through enhanced operational efficiency and sustained revenue growth.


Latest News

Mitsubishi Tanabe Pharma Corporation and CEO Akihisa Harada Recent News

Mitsubishi Tanabe Pharma Corporation was acquired by Bain Capital in February 2025 for $3.3 billion and has since changed its name to Tanabe Pharma Corporation, effective December 1, 2025, reflecting its commitment to global growth and innovation. Akihisa Harada, former Pfizer Japan president, became CEO on September 1, 2025, leading the company in a period of strategic shifts including the ending of a co-promotion agreement for Janssen's Stelara(r) in Japan by the end of 2025.
Source: http://www.baincapital.com/news/bain-capital-acquire-mitsubishi-tanabe-pharma-corporation



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Mitsubishi Tanabe Pharma Corporation are subject to change from time to time.

Comments

No comment yet